PCN8 Axitinib (AXI) and Best Supportive Care (BSC) in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC)- Results of a Simulated Treatment Comparison (STC) Analyses
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1203
https://www.valueinhealthjournal.com/article/S1098-3015(12)02916-6/fulltext
Title :
PCN8 Axitinib (AXI) and Best Supportive Care (BSC) in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC)- Results of a Simulated Treatment Comparison (STC) Analyses
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02916-6&doi=10.1016/j.jval.2012.08.1203
First page :
A410
Section Title :
Cancer
Open access? :
No
Section Order :
705